Liposome-mediated combinatorial cytokine gene therapy induces localized synergistic immunosuppression and promotes long-term survival of cardiac allografts

Journal of Immunology

Volumn 174, Issue 11, 2005, Pages 6983-6992

  Furukawa, Hiroshi ^a   Oshima, Kiyohiro ^a   Tung, Thomas ^a   Cui, Guanggen ^a   Laks, Hillel ^a   Sen, Luyi ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 4; LIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIAC GRAFT REJECTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENTIATION; EX VIVO STUDY; GENE EXPRESSION; GENE OVEREXPRESSION; GENE THERAPY; GENE TRANSFER; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; LYMPHOCYTIC INFILTRATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TRANSGENE;

EID: 18944400713     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.174.11.6983     Document Type: Article

References (45)

1. Cotts, W. G., and M. R. Johnson. 2001. The challenge of rejection and cardiac allograft vasculopathy. Heart Fail. Rev. 6: 227-240.
2. Zuckermann, A., H. Reichenspurner, T. Birsan, H. Treede, E. Deviatko, B. Reichart, and W. Klepetko. 2003. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial. J. Thorac. Cardiovasc. Surg. 125: 891-900.
3. Kita, Y., X. K. Li, M. Ohba, N. Funeshima, S. Enosawa, A. Tamura, K. Suzuki, H. Amemiya, S. Hayashi, T. Kazui, and S. Suzuki. 1999. Prolonged cardiac allograft survival in rats systemically injected adenoviral vectors containing CTLA4Ig-gene. Transplantation 68: 758-766.
4. Sen, L., Y. S. Hong, H. Luo, G. Cui, and H. Laks. 2001. Efficiency, efficacy, and adverse effects of adenovirus- vs. liposome-mediated gene therapy in cardiac allografts. Am. J. Physiol. 281: H1433-H1441.
5. Moore, K. W., A. O'Garra, R. de Waal Malefyt, P. Vieira, and T. R. Mosmann. 1993. Interleukin-10. Annu. Rev. Immunol. 11: 165-190.
6. Morita, Y., M. Yamamoto, M. Kawashima, T. Aita, S. Harada, H. Okamoto, H. Inoue, and H. Makino. 2001. Differential in vitro effects of IL-4, IL-10 and IL-13 on proinflammatory cytokine production and fibroblast proliferation in rheumatoid synobium. Rheumatol. Int. 20: 49-54.
7. de Waal Malefyt, R., J. Abrams, B. Bennett, C. G. Figdor, and J. E. de Vries. 1991. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 174: 1209-1220.
8. Fiorentino, D. F., A. Zlotnik, T. R. Mosmann, M. Howard, and A. O'Garra. 1991. IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147: 3815-3822.
9. Fiorentino, D. F., M. W. Bond, and T. R. Mosmann. 1989. Two types of mouse T helper cell. J. Exp. Med. 170: 2081-2095.
10. Nemoto, Y., T. Otsuka, H. Niiro, K. Izuhara, K. Yamaoka, H. Nakashima, and Y. Niho. 1999. Differential effects of interleukin-4 and interleukin-10 on nitric oxide production by murine macrophages. Inflamm. Res. 48: 643-650.
11. de Waal Malefyt, R., J. Haanen, H. Spits, M. G. Roncarolo, A. te Velde, C. Figdor, K. Johnson, R. Kastelein, H. Yssel, and J. E. de Vries. 1991. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J. Exp. Med. 174: 915-924.
12. Qian, S., W. Li, W. Li, F. Fu, L. Lu, J. J. Fung, and A. W. Thomson. 1996. Systemic administration of cellular interleukin-10 can exacerbate cardiac allograft rejection. Transplantation 62: 1709-1714.
13. David, A., J. Chetritt, C. Guillot, L. Tesson, J. M. Heslan, M. C. Cuturi, J. P. Soulillou, and I. Anegon. 2000. Interleukin-10 produced by recombinant adenovirus prolongs survival of cardiac allografts in rats. Gene Ther. 7: 505-510.
14. DeBruyne, L. A., K. Li, S. Y. Chan, L. Qin, D. K. Bishop, and J. S. Bromberg. 1998. Lipid-mediated gene transfer of viral IL-10 prolongs vascularized cardiac allograft survival by inhibiting donor-specific cellular and humoral immune responses. Gene Ther. 5: 1079-1087.
15. Brauner, R., M. Nonoyama, H. Laks, D. C. Drinkwater, S. McCaffery, T. Drake, A. J. Berk, L. Sen, and L. Wu. 1997. Intracoronary adenovirus-mediated transfer of immunosuppressive cytokine genes prolongs allograft survival. J. Thorac. Cardiovasc. Surg. 114: 923-933.
16. Hong, Y.-S., L. Sen, G. Cui, M. Nonoyam, T. Chong, and H. Laks. 2002. Localized immunosuppression in the cardiac allograft induced by a new liposome-mediated IL-10 gene therapy. J. Heart Lung Transplant. 21: 1188-1200.
17. Kaneko, K., Z. Wang, S. H. Kim, A. E. Morelli, P. D. Robbins, and A. W. Thomson. 2003. Dendritic cells genetically engineered to express IL-4 exhibit enhanced IL-12p70 production in response to CD40 ligation and accelerate organ allograft rejection. Gene Ther. 10: 143-152.
18. Morris, S. C., W. C. Gause, and F. D. Finkelman. 2000. IL-4 suppression of in vivo T cell activation and antibody production. J. Immunol. 164: 1734-1740.
19. Schmidt-Weber, C. B., S. I. Alexander, L. E. Henault, L. James, and A. H. Lichtman. 1999. IL-4 enhances IL-10 gene expression in murine Th2 cells in the absence of TCR engagement. J. Immunol. 162: 238-244.
20. Oswald, I. P., R. T. Gazzinelli, A. Sher, and S. L. James. 1992. IL-10 synergizes with IL-4 and transforming growth factor-β to inhibit macrophage cytotoxic activity. J. Immunol. 148: 3578-3582.
21. Powrie, F., S. Menon, and R. L. Coffman. 1993. Interleukin-4 and interleukin-10 synergize to inhibit cell-mediated immunity in vivo. Eur. J. Immunol. 23: 2223-2229.
22. Lubberts, E., L. A. Joosten, M. M. Helsen, and W. B. van den Berg. 1998. Regulatory role of interleukin 10 in joint inflammation and cartilage destruction in murine streptococcal cell wall (SCW) arthritis: more therapeutic benefit with IL-4/IL-10 combination therapy than with IL-10 treatment alone. Cytokine 10: 361-369.
23. van Roon, J. A., J. W. Bijlsma, and F. P. Lafeber. 2002. Suppression of inflammation and joint destruction in rheumatoid arthritis may require a concerted action of Th2 cytokines. Curr. Opin. Investig. Drugs 3: 1011-1016.
24. Faust, A., H. Rothe, U. Schade, E. Lampeter, and H. Kolb. 1996. Primary non-function of islet grafts autoimmune diabetic nonobese diabetic mice is prevented by treatment with interleukin-4 and interleukin-10. Transplantation 62: 648-652.
25. Ko, K. S., M. Lee, J. J. Koh, and S. W. Kim. 2001. Combined administration of plasmids encoding IL-4 and IL-10 prevents the development of autoimmune diabetes in nonobese diabetic mice. Mol. Ther. 4: 313-316.
26. Rabinovitch, A., W. L. Suarez-Pinzon, O. Sorensen, R. C. Bleackley, R. F. Power, and R. V. Rajotte. 1995. Combined therapy with interleukin-4 and interleukin-10 inhibits autoimmune diabetes recurrence in syngeneic islet-transplanted nonobese diabetic mice. Transplantation 60: 368-374.
27. Oshima, K., H. Laks, G. Cui, T. Tung, and L. Sen. 2002. Interleukin-10 gene targeting induces apoptosis of alloreactive T cells via Fas/FasL pathway. Transplantation 73: 1019-1026.
28. Tung, T. C., K. Oshima, G. Cui, H. Laks, and L. Sen. 2003. Dual upregulation of Fas and Bax promotes alloreactive T cell apoptosis in IL-10 gene targeting of cardiac allografts. Am. J. Physiol. 285: H964-H973.
29. Perkins, H. D., B. H. van Leeuwen, C. M. Hardy, and P. J. Kerr. 2000. The complete cDNA sequences of IL-2, IL-4, IL-6 and IL-10 from the European rabbit (Oryctolagus cuniculus). Cytokine 12: 555-565.
30. Lipman, M. L., A. C. Stevens, and T. B. Strom. 1994. Heightened intragraft CTL gene expression in acutely rejecting renal allografts. J. Immunol. 152: 5120-5127.
31. Liu, C.-Y., A. Shiraishi, C. W.-C. Kao, R. L. Converse, J. L. Funderburgh, L. M. Corpuz, G. W. Conrad, and W. W.-Y Kao. 1998. The cloning of mouse keratocan cDNA and genomic DNA and the characterization of its expression during eye development. J. Biol. Chem. 273: 22584-22588.
32. Akazawa, H., S. Komazaki, H. Shimomura, F. Terasaki, Y. Zou, H. Takano, T. Nagai, and I. Komuro. 2004. Diphtheria toxin-induced autophagic cardiomyocyte death plays a pathogenic role in mouse model of heart failure. J. Biol. Chem. 279: 41095-41103.
33. Billingham, M. E., N. R. Cary, M. E. Hammond, J. Kemnitz, C. Marboe, H. A. McCallister, D. C. Snovar, G. L. Winters, and A. Zerbe. 1990. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: heart rejection study group. J. Heart Lung Transplant. 9: 587-593.
34. Dalesandro, J., H. Akimoto, C. M. Gorman, T. O. McDonald, R. Thomas, H. D. Liggitt, and M. D. Allen. 1996. Gene therapy for donor hearts: ex vivo liposome-mediated transfection. J. Thorac. Cardiovasc. Surg. 111: 416-421.
35. Stewart, M. J., G. E. Plautz, L. D. Buono, Z. Y. Yang, L. Xu, X. Gao, L. Huang, E. G. Nabel, and G. J. Nabel. 1992. Gene transfer in vivo with DNA-liposome complexes: safety and acute toxicity in mice. Hum. Gene Ther. 3: 267-275.
36. Stephan, D. J., Z. Y. Yang, H. San, R. D. Simari, C. J. Wheeler, P. L. Felgner, D. Gordon, G. J. Nabel, and E. G. Nabel. 1996. A new cationic liposome DNA complex enhances the efficiency of arterial gene transfer in vivo. Hum. Gene Ther. 7: 1803-1812.
37. Lin, A. J., N. L. Slack, A. Ahmad, C. X. George, C. E. Samuel, and C. R. Safinya. 2003. Three-dimensional imaging of lipid gene-carriers: membrane charge density controls universal transfection behavior in lamellar cationic liposome-DNA complexes. Biophys. J. 84: 3307-3316.
38. Arsic, N., L. Zentilin, S. Zacchigna, D. Santoro, G. Stanta, A. Salvi, G. Sinagra, and M. Giacca. 2003. Induction of functional neovascularization by combined VEGF and angiopoietin-1 gene transfer using AAV vectors. Mol. Ther. 7: 450-459.
39. Lee, M., K. S. Ko, S. Oh, and S. W. Kim. 2003. Prevention of autoimmune insulitis by delivery of a chimeric plasmid encoding interleukin-4 and interleukin-10. J. Control Release 88: 333-342.
40. Rizzo, L. V., R. A. Morawetz, N. E. Miller-Rivero, R. Choi, B. Wiggert, C. C. Chan, H. C. Morse III, R. B. Nussenblatt, and R. R. Caspi. 1999. IL-4 and IL-10 are both required for the induction of oral tolerance. J. Immunol. 162: 2613-2622.
41. Rogy, M. A., B. G. Beinhauer, W. Reinisch, L. Huang, and P. Pokieser. 2000. Transfer of interleukin-4 and interleukin-10 in patients with severe inflammatory bowel disease of the rectum. Hum. Gene Ther. 11: 1731-1741.
42. van Roon, J. A., F. P. Lafeber, and J. W. Bijlsma. 2001. Synergistic activity of interleukin-4 and interleukin-10 in suppression of inflammation and joint destruction in rheumatoid arthritis. Arthritis Rheum. 44: 3-12.
43. Mulligan, M. S., R. L. Warner, J. E. McDuffie, S. F. Bolling, J. V. Sarma, and P. A. Ward. 2000. Regulatory role of Th-2 cytokines, IL-10 and IL-4, in cardiac allograft rejection. Exp. Mol. Pathol. 69: 1-9.
44. Yamakami, K., S. Akao, T. Tadakuma, Y. Nitta, J. Miyazaki, and N. Yoshizawa. 2002. Administration of plasmids expressing interleukin-4 and interleukin-10 causes BALB/c mice to induce a T helper 2-type response despite the expected T helper 1-type response with a low-dose infection of Leishmania major. Immunology 105: 515-523.
45. Wang, P., P. Wu, M. I. Siegel, R. W. Egan, and M. M. Billah. 1995. Interleukin (IL)-10 inhibits nuclear factor κB (NFκB) activation in human monocytes: IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J. Biol. Chem. 270: 9558-9563.